FDA Approves GlaxoSmithKline (GSK) and Flamel Technologies (FLML) Once-a-Day COREG CR
More News related to FLML
- Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call
- Flamel Technologies Announces Licensing Agreement with Pfizer
- Flamel Technologies to Present at UBS Global Life Sciences Conference
- Baxter (BAX) and Flamel Technologies (FLML) Announce Collaboration to Formulate Longer Acting Forms of Blood Clotting Factors
- Flamel Tech. (FLML) Reports Q4 Loss of $0.11
More News related to GSK
- CORRECTING and REPLACING GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Trading Outlook for Advanced Life Sciences Holdings Inc. Issued by InvestorSoup.com
- Antigenics (AGEN) Indicated that Glaxo's malaria Vaccine Phase III Enrolled 5000 Children to Date
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
GlaxoSmithKline (NYSE: GSK) and Flamel Technologies (Nasdaq: FLML) announced FDA approval of once-a-day Coreg CR extended-release capsules, for the treatment of three cardiovascular conditions: high blood pressure, a heart attack that has reduced how well the heart pumps, Mild to severe heart failure.
COREG CR will utilize Flamel's proprietary Micropump technology, which controls the delivery of carvedilol helping to maintain appropriate amounts of medicine in the body over a 24-hour span. This technology allows COREG CR to be dosed once daily, in contrast to immediate-release COREG (carvedilol) tablets, which patients must take twice daily. GlaxoSmithKline plans to begin shipping COREG CR in the first quarter of 2007.
Related Categories
FDAStocks Mentioned
+0.03
-0.16Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
